16817-90-6

Basic information

• Product Name: 2-Amino-N-cyclohexylacetamide
• Synonyms: 2-AMINO-N-CYCLOHEXYL-ACETAMIDE;Acetamide, 2-amino-N-cyclohexyl-
• CAS NO: 16817-90-6
• Molecular Formula: C₈H₁₆N₂O
• Molecular Weight: 156.23
• Mol File: 16817-90-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 334.9 °C at 760 mmHg
• Flash Point: 156.4 °C
• Appearance: /
• Density: 1.03 g/cm³
• CAS DataBase Reference: 2-Amino-N-cyclohexylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Amino-N-cyclohexylacetamide(16817-90-6)
• EPA Substance Registry System: 2-Amino-N-cyclohexylacetamide(16817-90-6)

Safety Data

• Hazardous Substances Data: 16817-90-6(Hazardous Substances Data)

Usage

General Description

2-Amino-N-cyclohexylacetamide is a chemical compound with the molecular formula C8H16N2O. It is commonly used as a building block in the synthesis of pharmaceuticals and agrochemicals. 2-Amino-N-cyclohexylacetamide is known for its analgesic and anti-inflammatory properties and is often used in the development of pain-relieving medications. It works by affecting the central nervous system and reducing pain signals to the brain. Additionally, 2-Amino-N-cyclohexylacetamide has been studied for its potential use in treating neuropathic pain and other neurological disorders. Its structure and pharmacological properties make it a promising candidate for further research and development in the pharmaceutical industry.

Upstream product

• 4530-20-5 BOC-glycine 
• 108-91-8 cyclohexylamine 
• 33952-53-3 cyclohexylcarbamoylmethylcarbamic acid t-butyl ester 
• 3496-41-1 cyclohexyl carbamoylmethyl carbamic acid benzyl ester 
• 666177-21-5 N-(5-methyl-1-benzotriazolecarbonyl)glycine cyclohexylamide 
• 14432-20-3 α-N-Formylamino-N'-cyclohexylacetamid 
• 5373-25-1 N-(toluene-4-sulfonyl)-glycine cyclohexylamide 
• 2185-00-4 1,3-oxazolidine-2,5-dione 
• 5577-68-4 cyclohexylamino-trimethyl-silane 

Downstream Products

• 1403957-50-5 3-(N-(2-cyclohexylamino-2-oxoethyl)-N-sulfamoyl)benzamidine 
• 1403957-51-6 3-(N-(2-cyclohexylamino-2-oxoethyl)-N-sulfamoyl)benzamidinium trifluoroacetate 
• 1372089-88-7 2-(3-cyanophenylsulfonamido)-N-cyclohexylacetamide 
• 1448524-00-2 2-(4-bromophenoxy)-N-[(cyclohexylcarbamoyl)methyl]acetamide 
• 1448524-01-3 N-[(cyclohexylcarbamoyl)methyl]-2-(4-fluorophenoxy)acetamide 
• 99976-73-5 1-cyclohexylpiperazin-2-one 

Relevant articles and documents

Amido pyrimidine compound

The invention provides an amido pyrimidine compound with a novel structure as shown in a formula (I) and a preparation method and application of the amido pyrimidine compound. The amido pyrimidine compound is a compound shown as the formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer or tautomer thereof and the like. The amido pyrimidine compound provided bythe invention has a relatively good proliferation inhibition effect on various cancer cells; according to the present invention, the compound has characteristics of low tumor cell inhibition concentration, significantly-improved compound activity, good tumor cell selectivity and good solubility, and is expected to be a specific drug for treatment of malignant tumor cell abnormal proliferation diseases caused by EGFR mutation.

Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles

Nitrobenzothiazinone (BTZ) is a promising scaffold with potent activity against M. tuberculosis by inhibiting decaprenylphosphoryl-beta-d-ribose 2′-oxidase (DprE1). But unfavorable durability poses a challenge to further development of this class of agents. Herein, a series of BTZs bearing a variety of different substituents at the C-2 position were designed and synthesized. Compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Ra and were profiled for metabolic stability, plasma protein-binding capacity and pharmacokinetics in vivo. In general, these new BTZs containing N-piperazine, N-piperidine or N-piperidone moiety have excellent antitubercular activity and low cytotoxicity. Several of the compounds showed improved microsomal stability and lower plasma protein-binding, opening a new direction for further lead optimization. And we obtained compound 3o, which maintained good anti-tuberculosis activity (MIC = 8 nM) and presented better in vitro ADME/T and in vivo pharmacokinetic profiles than reported BTZ compound PBTZ169, which may serve as a candidate for the treatment of tuberculosis.

In silico and pharmacological screenings identify novel serine racemase inhibitors

d-Serine is a coagonist of the N-methyl-d-aspartate (NMDA)-type glutamate receptor and its biosynthesis is catalyzed by serine racemase (SR). The overactivation of the NMDA receptor has been implicated in the development of neurodegenerative diseases, strokes, and epileptic seizures, thus, the inhibitors of SR have potential against these pathological states. Here, we have developed novel inhibitors of SR by in silico screening and in vitro enzyme assay. The newly developed inhibitors have lower IC50 value comparing with that of malonate, one of the standard SR inhibitor. The structural features of novel inhibitors suggest the importance of central amide structure having a phenoxy substituent in their structure for the SR inhibitory activity. The present findings suggest the importance and rational development of new drugs for diseases of NMDAR overactivation.